Related Experiment Video

Updated: Jun 6, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report

Sina Haftchenary1, Miriam Avadisian, Patrick T Gunning

  • 1Department of Chemistry, University of Toronto, Mississauga, Canada.

Anti-Cancer Drugs
|November 11, 2010
PubMed

Insights

Aberrantly activated Signal Transducer and Activator of Transcription 3 (Stat3) drives cancer progression. This review highlights drug-like compounds that inhibit Stat3 signaling by disrupting protein interactions, offering new cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Signal transducer and activator of transcription 3 (Stat3) protein is aberrantly activated in numerous human cancers.
  • Constitutively active Stat3 promotes cancer progression and survival by upregulating protooncogenes.
  • Stat3 signaling is a critical target for cancer therapy.

Purpose of the Study:

  • To review recent advancements in identifying drug-like compounds targeting aberrant Stat3 signaling.
  • To focus on inhibitors that disrupt Stat3 protein-protein interactions.

Main Methods:

  • Literature review of recent research on Stat3 inhibitors.
  • Analysis of compounds targeting Stat3 protein-protein interactions.

Main Results:

  • Identification of various drug-like compounds with Stat3 inhibitory potential.
  • Demonstration of Stat3 protein-protein interaction disruption as a viable therapeutic strategy.

Conclusions:

  • Targeting aberrant Stat3 signaling through protein-protein interaction inhibition is a promising approach for cancer treatment.
  • Development of novel Stat3 inhibitors could lead to new therapeutic options for various human cancers.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...